Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
- PMID: 2402015
- DOI: 10.1093/jnci/82.19.1539
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
Abstract
In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery. We then systematically quantitated tumor reduction by clinical, radiologic, and histopathologic evaluations. Five consecutive groups of 33 patients received cyclophosphamide, methotrexate, and fluorouracil (CMF); fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC); or fluorouracil, epirubicin, and cyclophosphamide (FEC). The regimens for the five groups were as follows: group 1, three cycles of CMF; group 2, four cycles of CMF; group 3, three cycles of FAC; group 4, four cycles of FAC; and group 5, three cycles of FEC. In response to primary chemotherapy, 157 of the 161 assessable patients showed measurable tumor shrinkage; progressive disease was documented in four. Tumor shrinkage to less than 3 cm was documented in 127 (81%) of the 157 women subjected to surgery, thus allowing a breast-saving procedure, rather than modified radical mastectomy, in these 127 women. Histopathologic complete remission was documented in seven patients. Tumor response was unrelated to age, menopausal status, DNA content (ploidy), [3H]thymidine-labeling index, drug combination used, or number of treatment cycles in excess of three. The degree of response was inversely proportional to the initial tumor size, and the frequency of response was greater in receptor-negative tumors. Severe vomiting and hair loss were less frequent with CMF than with anthracycline-containing regimens, and the frequency of severe leukopenia and thrombocytopenia was minimal. Our results challenge the classical indication for primary mastectomy by showing that use of full-dose primary chemotherapy, sequentially combined with conservative surgery and radiation, can offer an effective and safe alternative to women concerned about the preservation of body integrity.
Similar articles
-
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678. Cancer. 2002. PMID: 12124820 Clinical Trial.
-
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.J Clin Oncol. 1988 Apr;6(4):679-88. doi: 10.1200/JCO.1988.6.4.679. J Clin Oncol. 1988. PMID: 2895801 Clinical Trial.
-
Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.J Natl Cancer Inst. 2004 Dec 15;96(24):1823-31. doi: 10.1093/jnci/djh338. J Natl Cancer Inst. 2004. PMID: 15601638 Clinical Trial.
-
[Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].Magy Onkol. 2002;46(4):307-13. Epub 2003 Feb 1. Magy Onkol. 2002. PMID: 12563352 Review. Hungarian.
-
Adjuvant chemotherapy in early breast cancer.Dan Med J. 2016 May;63(5):B5222. Dan Med J. 2016. PMID: 27127018 Review.
Cited by
-
[Preoperative irradiation and interstitial radiotherapy-hyperthermia boost in breast tumors > or = 3 cm. The Düsseldorf experience].Strahlenther Onkol. 1997 Oct;173(10):519-23. doi: 10.1007/BF03038468. Strahlenther Onkol. 1997. PMID: 9381361 German.
-
Preoperative chemotherapy in operable breast cancer. The influence of timing FEC in relation to surgery.Drugs. 1993;45 Suppl 2:31-7; discussion 36-7. doi: 10.2165/00003495-199300452-00006. Drugs. 1993. PMID: 7693419 Review.
-
Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer.World J Oncol. 2010 Aug;1(4):167-172. doi: 10.4021/wjon223w. Epub 2010 Aug 29. World J Oncol. 2010. PMID: 29147200 Free PMC article.
-
Postmastectomy Radiation in Breast Cancer Patients With Pathologically Positive Lymph Nodes After Neoadjuvant Chemotherapy: Usage Rates and Survival Trends.Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):549-559. doi: 10.1016/j.ijrobp.2017.06.2458. Epub 2017 Jun 28. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280449 Free PMC article.
-
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.Br J Cancer. 2013 Mar 5;108(4):866-72. doi: 10.1038/bjc.2012.547. Epub 2013 Jan 8. Br J Cancer. 2013. PMID: 23299526 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical